Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California

MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ:PETV & PETVW) (the “Company” or “PetVivo”) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that Alexander Amalfitano DVM, of Ethos Veterinary Health and Colorado Animal Specialty & Emergency (CASE) presented at the Veterinary Orthopedic Society (“VOS”) annual conference on the completion of the first cohort of dogs in a clinical study, which examined the benefit and tolerability of an intra-articular injection of collagen-elastin hydrogel microparticles (i.e. Spryng^™ with OsteoCuhsion^™ Technology) into the coxofemoral joint of dogs with osteoarthritis.

Read more at globenewswire.com